Contrasting Pathfinder Cell Therapy (OTCMKTS:PFND) and ReWalk Robotics (NASDAQ:LFWD)

Pathfinder Cell Therapy (OTCMKTS:PFND) and ReWalk Robotics (NASDAQ:LFWD) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, earnings, institutional ownership, dividends, valuation, analyst recommendations and risk.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Pathfinder Cell Therapy and ReWalk Robotics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pathfinder Cell Therapy	0	0	0	0	N/A
ReWalk Robotics	0	0	1	1	3.50

ReWalk Robotics has a consensus target price of $13.00, indicating a potential upside of 219.41%.

Profitability

This table compares Pathfinder Cell Therapy and ReWalk Robotics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pathfinder Cell Therapy	N/A	N/A	N/A
ReWalk Robotics	-134.52%	-35.41%	-27.64%

Earnings & Valuation

This table compares Pathfinder Cell Therapy and ReWalk Robotics’ revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pathfinder Cell Therapy	N/A	N/A	N/A	N/A	N/A
ReWalk Robotics	$13.85 million	2.56	-$22.13 million	($3.11)	-1.31

Pathfinder Cell Therapy has higher earnings, but lower revenue than ReWalk Robotics.

Insider and Institutional Ownership

26.8% of ReWalk Robotics shares are held by institutional investors. 15.1% of Pathfinder Cell Therapy shares are held by company insiders. Comparatively, 2.1% of ReWalk Robotics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

About Pathfinder Cell Therapy

Pathfinder Cell Therapy, Inc., a development stage regenerative medicine company, focuses on developing novel cell-derived and related therapies for the treatment of various diseases and medical conditions characterized by organ-specific cell damage. It identifies diabetes, renal disease, myocardial infarction, peripheral vascular disease, and other diseases as potential indications for therapies based on its technology. The company was founded in 2008 and is headquartered in Cambridge, Massachusetts.

About ReWalk Robotics

ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke. The company markets and sells its products directly to institutions and individuals, as well as through third-party distributors. The company was formerly known as Argo Medical Technologies Ltd. ReWalk Robotics Ltd. was incorporated in 2001 and is headquartered in Yokneam Illit, Israel.